Open AccessImpact of Renin‐Angiotensin System Inhibitors on Long‐Term Clinical Outcomes of Patients With Coronary Artery Spasm
Author(s) -
Choi Byoung Geol,
Jeon Sung Yeon,
Rha SeungWoon,
Park SangHo,
Shim Min Suk,
Choi Se Yeon,
Byun Jae Kyeong,
Li Hu,
Choi Jah Yeon,
Park Eun Jin,
Park SungHun,
Lee Jae Joong,
Lee Sunki,
Na Jin Oh,
Choi Cheol Ung,
Lim Hong Euy,
Kim Jin Won,
Kim Eung Ju,
Park Chang Gyu,
Seo Hong Seog,
Oh Dong Joo
Publication year - 2016
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.116.003217
Subject(s) - medicine , ace inhibitor , cardiology , propensity score matching , coronary artery disease , incidence (geometry) , endothelial dysfunction , angina , provocation test , myocardial infarction , angiotensin converting enzyme , pathology , blood pressure , physics , optics , alternative medicine
Background Coronary artery spasm ( CAS ) is a well‐known endothelial dysfunction, and a major cause of vasospastic angina ( VSA ). The renin–angiotensin system ( RAS ) is known to be closely associated with endothelial function. However, there are only a few studies that investigated the impact of RAS inhibitor on long‐term clinical outcomes in VSA patients. Methods and Results A total of 3349 patients with no significant coronary artery disease, diagnosed with CAS by acetylcholine provocation test were enrolled for this study. Significant CAS was defined as having ≥70% narrowing of the artery after incremental injections of 20, 50, and 100 μg of acetylcholine into the left coronary artery. Patients were divided into 2 groups according to whether the prescription included RAS inhibitor or not ( RAS inhibitor group: n=666, non‐ RAS inhibitor group; n=2683). To adjust for any potential confounders that could cause bias, propensity score matching ( PSM ) analysis was performed using a logistic regression model. After PSM analysis, 2 matched groups (524 pairs, n=1048 patients, C‐statistic=0.845) were generated and their baseline characteristics were balanced. During the 5‐year clinical follow‐up, the RAS inhibitor group showed a lower incidence of recurrent angina (8.7% versus 14.1%, P =0.027), total death (0.0% versus 1.3%, P =0.045), and total major adverse cardiovascular events (1.0% versus 4.1%, P =0.026) than the non‐ RAS inhibitor group. Conclusions Chronic RAS inhibitor therapy was associated with lower incidence of cardiovascular events in VSA patients in the 5‐year clinical follow‐up.